Neogenomics, Inc.
NEO
$7.39
-$0.44-5.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.89% | 10.51% | 19.31% | 31.50% | 32.95% |
| Total Depreciation and Amortization | -1.38% | -0.05% | 0.60% | 1.74% | 3.76% |
| Total Amortization of Deferred Charges | 1.32% | 1.32% | 1.26% | 1.33% | 1.33% |
| Total Other Non-Cash Items | 17.47% | 19.05% | 21.75% | 20.41% | 20.41% |
| Change in Net Operating Assets | 23.05% | -28.00% | 32.23% | -35.20% | -55.43% |
| Cash from Operations | 150.15% | 459.60% | 164.07% | 100.77% | 69.43% |
| Capital Expenditure | -63.77% | -42.81% | -39.23% | -0.65% | 25.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -54.44% | -48.87% | -14.93% | 42.10% | 180.97% |
| Cash from Investing | -97.20% | -83.24% | -39.23% | 79.04% | 452.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 96.61% | 96.33% | 91.44% |
| Issuance of Common Stock | 25.66% | 12.46% | 7.36% | -0.96% | -33.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -39.52% | -39.52% | -29.80% | -29.80% | -29.80% |
| Cash from Financing | 19.74% | 2.02% | 2.81% | -5.01% | -44.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.64% | -69.08% | 38.99% | 1,114.11% | 285.90% |